Racura Oncology
- Company typePublic
- Founded2021
- HeadquartersSydney, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Racura Oncology firmographics
Firmographics- Name
- Racura Oncology
- Legal name
- Racura Oncology Limited
- Website
- https://racuraoncology.com
- Company type
- Public
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Racura Oncology industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro industry
- Oncology & Hematology Pharmaceuticals
Keywords
Where Racura Oncology is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices3 records
Markets served
Racura Oncology business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development & Commercialization: Pre-revenue clinical-stage biopharmaceutical company. The company is developing (E,E)-bisantrene (RC220) for multiple oncology indications. Revenue is expected upon regulatory approval and commercialization of the drug candidate.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Racura Oncology product offering
Product offeringCore offering
Racura Oncology is a clinical-stage biopharmaceutical company developing RC220, a proprietary reformulation of (E,E)-bisantrene, as an anticancer therapy with dual anticancer and cardioprotective properties. The lead asset targets multiple oncology indications including acute myeloid leukemia (AML), EGFR-mutated non-small cell lung cancer (NSCLC), and solid tumours in combination with doxorubicin, through Phase 1, Phase 1a/b, and Phase 3 clinical programs.
Product overview
Racura Oncology is a clinical-stage biopharmaceutical company developing RC220, a proprietary reformulation of (E,E)-bisantrene, as a targeted cancer therapy with unique cardioprotective properties. The company's product portfolio centers on RC220 as the lead asset, which is being advanced through multiple clinical programs: Phase 3 in acute myeloid leukemia (EMILI-3), Phase 1a/b in EGFR-mutated non-small cell lung cancer (HARNESS-1), and Phase 1 in solid tumours in combination with doxorubicin (CPACS). The company also maintains the original bisantrene formulation (RC110) with published Phase 2 clinical data. All formulations leverage the drug's mechanism of action involving G4-DNA and RNA binding to silence the MYC cancer growth regulator.
Differentiator
Problem solved
Functional benefit
Products and services
- RC220 Proprietary reformulated version of (E,E)-bisantrene designed to enable peripheral and central intravenous administration while maintaining pharmacokinetics and anticancer activity. Lead drug candidate with dual anticancer and cardioprotective properties for AML, EGFRm NSCLC, and solid tumours in combination with doxorubicin.
- Cardioprotection Blood Test Novel blood-based molecular test designed to assess the cardioprotective effects of lead drug candidate RC220 in cancer patients undergoing chemotherapy.
Quantifiable outcome
- 46% complete response rate in relapsed/refractory AML across 10 monotherapy studies with 146 patients
- +3 more outcomes
Companies that use Racura Oncology
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles3 records
Racura Oncology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Racura Oncology partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and minor.
- AstexcoreCollaboration with Astex, a leading precision medicine company, as part of Racura's global scientific and medical partnerships network.
- City of HopecoreExclusive licensing agreement with City of Hope for bisantrene development. City of Hope is a renowned cancer research and treatment institution.
- MD Anderson Cancer CentercoreCollaboration with MD Anderson, one of the world's most respected cancer centers, as part of global partnerships to advance bisantrene.
- Sheba City of HealthcorePartnership with Sheba Medical Center in Israel, where investigator-sponsored bisantrene trials in AML were conducted under Professor Arnon Nagler.
- UNC School of MedicinecoreCollaboration with University of North Carolina School of Medicine as part of Racura's global scientific and medical partnerships network.
- University of WollongongcoreAcademic partnership with University of Wollongong for bisantrene research and development. Professor Michael Kelso, VP of Research, is from this university.
- University of NewcastlecoreAcademic partnership with University of Newcastle as part of Racura's collaboration network for scientific research.
- Ardena Holding NVcoreManufacturing partnership with Ardena Holding NV to provide additional current Good Manufacturing Practice (cGMP) manufacturing for bisantrene.
- Purdue UniversitycorePartnership with Purdue University for molecular level studies on how (E,E)-bisantrene binds to the MYC-G4 DNA structure.
- Emory UniversitycoreCollaboration with Emory University as part of Racura's scientific partnerships network to advance understanding of bisantrene.
- George ClinicalcoreContract Research Organisation (CRO) appointed to support the Phase 1a/1b trial for RC220 bisantrene in solid tumour patients.
- Baker Heart and Diabetes InstituteminorAssociate Professor Erin Howden from the Baker Heart and Diabetes Institute joined Racura's Scientific Advisory Board to provide expertise on cardiometabolic effects of chemotherapy.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Racura Oncology competitors and assessment
Company assessmentRegional players
- Kazia Therapeutics: Australian clinical-stage oncology company developing small-molecule drugs for brain cancers and other solid tumors. Comparable as a small ASX-listed biotech with an oncology pipeline.
- Imugene: Australian clinical-stage immuno-oncology company developing B-cell vaccines and oncolytic virotherapy. Comparable as a small ASX-listed oncology biotech advancing multiple clinical programs.
- Opthea: Australia-based clinical-stage developer of oncology therapeutics. Geographic and stage peer to Racura, though Opthea focuses on ophthalmology-related VEGF therapies rather than cytotoxic chemotherapy.
Broad incumbents
- AbbVie: Global pharmaceutical company with venetoclax (Venclexta), a leading AML therapy. Represents the established competitive standard-of-care that any new AML entrant must address.
- Servier Pharmaceuticals: Global pharmaceutical company with significant AML franchise (Tibsovo, idhifa) and oncology pipeline. Represents the established competitive landscape in hematologic oncology.
- Astellas Pharma: Global pharmaceutical company with established AML and oncology franchises, including gilteritinib. Sets the competitive bar for AML drug approvals and reimbursement.
Emerging players
- Actinium Pharmaceuticals: US clinical-stage company developing targeted radiotherapies for AML and other hematologic malignancies. Comparable as a small-cap AML-focused developer at a similar clinical stage to Racura.
- Cylene Pharmaceuticals: Developer of small molecules targeting G-quadruplex (G4) DNA structures and MYC oncogene regulation. Directly comparable to Racura's G4-DNA/MYC mechanism of action for (E,E)-bisantrene, though at a different stage of development.
Direct peers
- Noxopharm: Australian clinical-stage oncology company developing small-molecule therapeutics. Comparable to Racura as a similarly small ASX-listed biotech pursuing oncology indications with limited commercial revenue.
- Cyclacel Pharmaceuticals: Clinical-stage oncology company developing small-molecule drugs with a primary focus on acute myeloid leukemia. Directly comparable to Racura's AML-led development strategy with RC220.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Racura Oncology social profiles
Digital presenceRacura Oncology compliance and trust
Trust signalCompliance2 records
Racura Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Racura Oncology leadership team
Management profileNumber of profiles
Profiles9 records
Racura Oncology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Racura Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Racura Oncology
What does Racura Oncology do?
Racura Oncology is a clinical-stage biopharmaceutical company developing RC220, a proprietary reformulation of (E,E)-bisantrene, as an anticancer therapy with dual anticancer and cardioprotective properties. The lead asset targets multiple oncology indications including acute myeloid leukemia (AML), EGFR-mutated non-small cell lung cancer (NSCLC), and solid tumours in combination with doxorubicin, through Phase 1, Phase 1a/b, and Phase 3 clinical programs.
Is Racura Oncology a public or private company?
Racura Oncology is a public company. It is classified as public and is currently operating.
When was Racura Oncology founded?
Racura Oncology was founded in 2021. It employs 11 to 50 people.
Where is Racura Oncology based?
Racura Oncology is headquartered in Sydney, Australia, in the Oceania region.
How does Racura Oncology make money?
One revenue line is on record: drug Development & Commercialization.
Who are Racura Oncology's main competitors?
Regional players on record are Kazia Therapeutics, Imugene and Opthea. Broad incumbents are AbbVie, Servier Pharmaceuticals and Astellas Pharma. Emerging players are Actinium Pharmaceuticals and Cylene Pharmaceuticals. Direct peers are Noxopharm and Cyclacel Pharmaceuticals.
Does Racura Oncology have an API?
No public API is recorded for Racura Oncology.
What industry is Racura Oncology in?
Racura Oncology's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.